此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

2026年9月8日 更新者:Anahita Dua, MBCHB, MBA, MSC、Massachusetts General Hospital

Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease

The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs.

The main questions it aims to answer are:

  • Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure?
  • Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment?

Researchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better.

Participants will:

  • Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure
  • Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure
  • Have medications adjusted based on blood test results if assigned to the TARGET group

研究概览

详细说明

SCIENTIFIC RATIONALE Graft and stent thrombosis occurs in approximately 17% of PAD patients within 6 months of lower extremity revascularization and is the leading driver of amputation and death in this population. Current standard-of-care (SOC) thromboprophylaxis applies a uniform antiplatelet regimen despite well-documented inter-patient variability in platelet reactivity and drug response - up to 60-65% of PAD patients demonstrate resistance to aspirin or clopidogrel. The absence of personalized, objective thromboprophylaxis strategies represents a critical gap in PAD management.

TECHNOLOGY: THROMBOELASTOGRAPHY WITH PLATELET MAPPING (TEG-PM)

TEG-PM is a whole-blood, point-of-care assay providing real-time assessment of a patient's complete coagulation profile. TEG characterizes clot initiation (R time), kinetics (K time, α angle), maximum clot strength (mA), and fibrinolysis (Lysis 30), enabling discrimination between hypo- and hypercoagulable states. Platelet Mapping quantifies platelet inhibition via arachidonic acid (AA) and adenosine diphosphate (ADP) agonist assays, yielding a platelet inhibition percentage that reflects each patient's real-time pharmacodynamic response to antiplatelet therapy. All samples are analyzed on a TEG 6s (Haemonetics®) Hemostasis Analyzer within validated processing windows using citrated and sodium heparin tubes.

PRELIMINARY DATA A prospective observational study of 162 PAD patients identified platelet inhibition as the sole independent predictor of post-revascularization thrombosis. A threshold of 29% identified high thrombotic risk (87% sensitivity, 71% specificity; AUC 0.756), while an upper threshold of 86% identified elevated bleeding risk (71% sensitivity, 87% specificity; AUC 0.84), defining a therapeutic window of 29-86%. A separate analysis of 521 TEG-PM samples from 143 PAD patients confirmed extensive inter-patient variability in platelet inhibition response, supporting the case against uniform treatment strategies.

Pilot implementation in 34 patients produced a thrombosis rate of 3.8% vs. 20% under SOC (p<0.05) with no increase in bleeding. A subsequent prospective comparison of 70 protocol-guided patients against 267 SOC patients demonstrated thrombosis rates of 4.3% vs. 20.6%, with fewer bleeding events in the protocol-guided arm.

THE TARGET PROTOCOL The Thromboprophylaxis for Arterial Revascularization to Guide Elderly Therapy (TARGET) protocol integrates serial TEG-PM assessments into clinical decision-making to maintain platelet inhibition within the 29-86% therapeutic window throughout 12 months. TEG-PM is first performed at 7 days postoperatively. If platelet inhibition falls outside the therapeutic range, the antiplatelet regimen is adjusted per a prespecified escalation/de-escalation algorithm, with repeat testing 7 days after each change. Once the target range is achieved, monitoring continues at 1, 3, 6, 9, and 12 months with adjustments made as needed. Patients refractory to stepwise adjustments are referred to hematology once for further evaluation and remain enrolled on their last recommended regimen. All patients who receive clopidogrel for at least 7 days undergo VerifyNow P2Y12 resistance testing at a single timepoint to inform agent selection. Control arm patients receive SOC therapy throughout; TEG-PM is collected for data purposes only with no medication adjustments made.

COAGULATION TESTING SCHEDULE TEG-PM samples are collected at: preoperative baseline, 1 week (7-20 days post-op), 1 month (27-47 days), 3 months (85-105 days), 6 months (180-210 days), 9 months (270-295 days), and 12 months (365-390 days). Unscheduled samples may be collected at the PI's discretion in response to clinical events such as thrombosis, bleeding, or inconclusive results.

研究类型

介入性

注册 (估计的)

484

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
        • 接触:
        • 接触:
      • Salem、Massachusetts、美国、01970
        • 招聘中
        • Salem Hospital (Mass General Brigham)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and/or closed revascularization.
  • Patients at the age of 18 or older

Exclusion Criteria:

  • Patients who are younger than 18 years old
  • Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)
  • Prisoners, defined as those who have been directly admitted from a correctional facility.
  • No atherosclerosis
  • Subject has active stomach ulcers
  • Subject has severe hepatic impairment
  • Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of >1 year, the study team will consult with the

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:TARGET
Participants receive postoperative antiplatelet therapy consistent with standard of care, with regimen adjustments guided by serial TEG-PM (Thromboelastography with Platelet Mapping) assessments. The goal is to maintain platelet inhibition within a therapeutic window of 29-86%. If platelet inhibition falls outside this range at any timepoint, the antiplatelet regimen is escalated or de-escalated per a prespecified algorithm. TEG-PM testing occurs at 1 week, 1, 3, 6, 9, and 12 months postoperatively, with repeat testing 7 days after any medication change.
Aspirin is an oral antiplatelet agent that inhibits cyclooxygenase-mediated thromboxane A2 production, reducing platelet aggregation. It serves as the foundational antiplatelet agent in both study arms following lower extremity endovascular revascularization.
其他名称:
  • Acetylsalicylic Acid; ASA
Clopidogrel is an oral P2Y12 platelet inhibitor used as part of postoperative antiplatelet therapy following lower extremity endovascular revascularization. In the SOC arm, it is administered as part of a fixed dual antiplatelet regimen. In the TARGET arm, it serves as an initial antiplatelet agent, with continuation or substitution determined by TEG-PM platelet inhibition results and VerifyNow P2Y12 resistance testing. If clopidogrel resistance is identified or platelet inhibition remains below the 29% threshold, clopidogrel may be replaced with ticagrelor per the study algorithm.
其他名称:
  • 波立维
Ticagrelor is an oral, reversible P2Y12 platelet inhibitor. Unlike clopidogrel, ticagrelor demonstrates minimal resistance and more consistent platelet inhibition, making it a preferred escalation agent.
其他名称:
  • 布里林塔
Rivaroxaban is an oral factor Xa inhibitor used in both study arms. In the SOC arm, low-dose rivaroxaban combined with aspirin represents one of two standard postoperative regimens, administered per surgeon preference. In the TARGET arm, rivaroxaban may be initiated or substituted based on TEG-PM platelet inhibition results and clopidogrel resistance testing findings. Full-dose rivaroxaban is reserved for patients who remain persistently hypercoagulable despite stepwise antiplatelet escalation, prior to hematology referral.
其他名称:
  • 拜瑞妥
Whole-blood, viscoelastic point-of-care assay used to assess real-time coagulation status and platelet function.
其他名称:
  • TEG-PM
  • TEG 6s
  • Haemonetics TEG 6s Hemostasis Analyzer
有源比较器:Standard of Care (SOC)
Participants receive standard postoperative antiplatelet therapy per the treating surgeon's preference (dual antiplatelet therapy or aspirin combined with low-dose rivaroxaban) for the 12-month follow-up period. TEG-PM testing is performed at all scheduled timepoints for data collection purposes only; no medication adjustments are made based on results.
Aspirin is an oral antiplatelet agent that inhibits cyclooxygenase-mediated thromboxane A2 production, reducing platelet aggregation. It serves as the foundational antiplatelet agent in both study arms following lower extremity endovascular revascularization.
其他名称:
  • Acetylsalicylic Acid; ASA
Clopidogrel is an oral P2Y12 platelet inhibitor used as part of postoperative antiplatelet therapy following lower extremity endovascular revascularization. In the SOC arm, it is administered as part of a fixed dual antiplatelet regimen. In the TARGET arm, it serves as an initial antiplatelet agent, with continuation or substitution determined by TEG-PM platelet inhibition results and VerifyNow P2Y12 resistance testing. If clopidogrel resistance is identified or platelet inhibition remains below the 29% threshold, clopidogrel may be replaced with ticagrelor per the study algorithm.
其他名称:
  • 波立维
Ticagrelor is an oral, reversible P2Y12 platelet inhibitor. Unlike clopidogrel, ticagrelor demonstrates minimal resistance and more consistent platelet inhibition, making it a preferred escalation agent.
其他名称:
  • 布里林塔
Rivaroxaban is an oral factor Xa inhibitor used in both study arms. In the SOC arm, low-dose rivaroxaban combined with aspirin represents one of two standard postoperative regimens, administered per surgeon preference. In the TARGET arm, rivaroxaban may be initiated or substituted based on TEG-PM platelet inhibition results and clopidogrel resistance testing findings. Full-dose rivaroxaban is reserved for patients who remain persistently hypercoagulable despite stepwise antiplatelet escalation, prior to hematology referral.
其他名称:
  • 拜瑞妥
Whole-blood, viscoelastic point-of-care assay used to assess real-time coagulation status and platelet function.
其他名称:
  • TEG-PM
  • TEG 6s
  • Haemonetics TEG 6s Hemostasis Analyzer

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Arterial Thrombosis in the Treated Limb
大体时间:12 months post-revascularization
Proportion of participants experiencing graft or stent thrombosis in the revascularized limb, compared between the TARGET and SOC arms. Thrombosis will be assessed via vascular studies including ankle-brachial index, arterial duplex, and toe pressure at scheduled follow-up visits.
12 months post-revascularization

次要结果测量

结果测量
大体时间
Amputation-Free Survival (AFS)
大体时间:12 months post-revascularization
12 months post-revascularization
All-Cause Mortality
大体时间:12 months post-revascularization
12 months post-revascularization
Reintervention Rate
大体时间:12 months post-revascularization
12 months post-revascularization
Incidence of Bleeding Events
大体时间:12 months post-revascularization
12 months post-revascularization

其他结果措施

结果测量
措施说明
大体时间
Platelet Inhibition Level
大体时间:1 week, 1, 3, 6, 9, and 12 months post-revascularization
Serial TEG-PM derived platelet inhibition percentages tracked over time to assess maintenance within the therapeutic window of 29-86% in the TARGET arm.
1 week, 1, 3, 6, 9, and 12 months post-revascularization
Rutherford Score
大体时间:1 week, 1, 3, 6, 9, and 12 months post-revascularization

The Rutherford Classification System is a standardized seven-category scale (Grade 0-6) used to classify the severity of peripheral artery disease based on clinical symptoms and hemodynamic measurements.

Category 0 indicates no symptoms with normal hemodynamic findings; Category 1 indicates mild claudication; Category 2 indicates moderate claudication; Category 3 indicates severe claudication; Category 4 indicates ischemic rest pain; Category 5 indicates minor tissue loss; and Category 6 indicates major tissue loss or gangrene.

Higher scores indicate worse limb ischemia and poorer functional status.

The score is assessed by the treating physician at each scheduled follow-up visit.

1 week, 1, 3, 6, 9, and 12 months post-revascularization
Clopidogrel Resistance
大体时间:Once during follow-up, through study completion, an average of 12 months post-revascularization
Assessed via VerifyNow P2Y12 assay in all patients who receive clopidogrel for at least 7 days during the study period.
Once during follow-up, through study completion, an average of 12 months post-revascularization
Wound Status
大体时间:1 week, 1, 3, 6, 9, and 12 months post-revascularization
Wound status at the revascularization site is assessed at each scheduled follow-up visit by clinical examination. Clinicians document the presence or absence of a wound and, if present, categorize its status as one of four categories: stable, better, worse, or new wound. Changes in wound status between visits are tracked over time and recorded in conjunction with overall limb status assessment including thrombosis, amputation, and reintervention events.
1 week, 1, 3, 6, 9, and 12 months post-revascularization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年4月29日

初级完成 (估计的)

2027年4月29日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2026年5月13日

首先提交符合 QC 标准的

2026年5月21日

首次发布 (实际的)

2026年5月29日

研究记录更新

最后更新发布 (实际的)

2026年9月11日

上次提交的符合 QC 标准的更新

2026年9月8日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅